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OBJECTIVES: In continuous outcome variables to be measures
of effectiveness in cost effectiveness/beneﬁt analysis, it is very
straightforward to estimate functions of cost and effectiveness
such as incremental cost effectiveness ratio(ICER), and incre-
mental net beneﬁt(INB). As well as life expectancy or survival
time, primary outcome variables in many clinical trials are count
data. Nevertheless, estimation or inference procedure of those
data is not well explained. Especially, measures of post treatment
in count data includes excessive zero due to treatment effect. In
this study, we provide and compare estimation strategies for
functions of cost and effectiveness which consist of counts using
Poisson, negative binomial, zero inﬂated Poisson model(includ-
ing regression model) and explore the properties of each model.
METHODS: Point and interval estimation of ICER and INB for
each model will be derived, and through the simulation study,
we compare power to assess the performance in various situa-
tions. Illustrative example was presented with “Randomised,
ﬂexible dose and open study to compare the efﬁcacy and safety
of Adalat Oros with ginkgo biloba extract to treat the patients
with the Raynaud’s disease”. RESULTS: On the ground of power
comparison and conﬁdence intervals of ICER and INB, ordinal
modeling of count data leaded to biased estimation of ICER and
INB. Compared to zero inﬂated Poisson model of ICER and INB,
simple estimation which count data were considered continuous
variable underestimated more than 1.5 times. CONCLUSION:
The study demonstrated the estimation procedure of cost and
effectiveness functions and appropriate modeling of count data
prevent biased estimate of ICER or INB.
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OBJECTIVES: To produce a simple probabilistic model for
guiding pharmaceutical pricing decisions, across multiple and
various health care markets, in the presence of uncertainty
regarding market-speciﬁc characteristics, access and share.
METHODS: Pharmaceutical pricing appears to be largely deter-
mined by the price levels within a drug class or indication with
less emphasis placed on cost effectiveness and budgetary impact.
Health payers by contrast are increasingly using cost-effective-
ness and budgetary impact measures to determine whether a
product should be reimbursed at the requested price. We set out
a simple system for probabilistically modelling manufacturer rev-
enues from a product as a function of product price. The system
relies on explicit modelling of the reimbursement probability as
a function of price, and of market share conditional on reim-
bursement as a function of price. Uncertainty can be incorpo-
rated at the patient and market level. A revenue probability
distribution function is derived as a function of price. RESULTS:
For single market models, the system produces the familiar “all
or nothing” results of lesser interest: lower prices equate to
greater probabilities of reimbursement and market share. The
system is most valuable in multi-market situations where rela-
tionships are more complex or in markets where, due to the pres-
ence of competitor products or reference pricing, the relationship
with price of probability of acceptance or level of market share
is complex. Results in these settings are less generalizable. We
demonstrate this system in a number of illustrative single and
multi-market settings. CONCLUSION: The revenue probability
distribution function provides a useful tool to guide pharma-
ceutical pricing decisions, according to a company’s risk proﬁle.
The model developed facilitates decisions as to when and how
to trade-off reimbursement probability for revenue per patient,
with the aim of maximal revenues at a global level.
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OBJECTIVES: The activities of pharmaceutical companies in
developing, pricing and marketing their products continues to be
controversial, and literatures exist on each subject, but very little
has been published modeling their joint determination.
METHODS: Using standard micro-economic assumptions of
proﬁt-maximization we develop a model of the decision-making
process which yields an interior equilibrium, solve the model and
conduct comparative statics analyses. RESULTS: We ﬁnd strong
relationships between marketing and research expenditure. Mar-
keting and research are not substitutes, but complements. Exoge-
nous changes in the research environment which lead to an
increase in research will lead to a more than one-for-one increase
in marketing. Increasing shares of pharmaceutical costs paid
directly by consumers will lead to a decrease in marketing. CON-
CLUSION: Empirical studies of ﬁrm behavior may yield biased
results if they do not consider the simultaneous nature of the
ﬁrm’s decisions.
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OBJECTIVES: To investigate the predictors of self-rated health
status for the U.S. civilian noninstitutionalized population.
METHODS: Cross-sectional analyses using multivariate logistic
regression were performed with 11,405 individuals from the
2003 MEPS. The self-rated health status was dichotomized into
two categories (fair/poor health and good/very good/excellent
health). Standard demographic variables were employed as pre-
dictors in the regression, and the impact of a given predictor on
the self-rated health status was obtained as odds ratios. To check
the presence of multicollinearity, the conditional index and vari-
ance composition were examined. RESULTS: Smaller family size,
very low incomes (less than $15,000/year), non-white ethnicity
(Hispanic, African-American, and Asian), older ages, female,
lower education than college, having public health insurance,
and having worse mental health status were signiﬁcantly and
consistently associated with fair/poor perceived health (p < 0.05).
An additional family member and male gender were related with
decreased risk of fair/poor perceived health by 0.88 and 0.87,
respectively. Subjects with very low incomes, Hispanic ethnicity,
and aged between 56 to 65 were associated with 1.19, 1.34, 
and 3.65 times more likely to rate their health as fair/poor in
comparison with subjects with high incomes (more than
$100,000/year), White ethnicity, and aged between 16 to 25,
respectively. Similarly, persons with lower education (high school
degree) and public insurance would be 1.77 and 1.75 times as
